Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;7(6):e70013.
doi: 10.1002/edm2.70013.

Plasma Glycated CD59 and Gestational Diabetes Mellitus: A Systematic Review

Zahra Asadi  1   2 , Roya Safari-Faramani  3 , Faranak Aghaz  4 , Asad Vaisi-Raygani  2   5 , Saba Jalilian  4
Affiliations

Plasma Glycated CD59 and Gestational Diabetes Mellitus: A Systematic Review

Zahra Asadi et al. Endocrinol Diabetes Metab. 2024 Nov.

Abstract

Aims: Gestational diabetes mellitus (GDM) is a common complication of pregnancy worldwide. The standard method for screening GDM is the 75 g oral glucose tolerance test (OGTT). However, the OGTT is difficult, time-consuming and requires fasting, making it an inconvenient test for GDM. Researchers have turned their attention to alternative biomarkers for GDM. This study aimed to systematically investigate the potential of plasma glycated CD59 (pGCD59) as a new biomarker for GDM and its associated adverse pregnancy outcomes.

Methods: The systematic review was performed in the PubMed, ISI Web of Science, Scopus and Google Scholar databases from 1/1/2000 to 4/1/2024, and relevant studies were selected based on the inclusion and exclusion criteria. The quality of the studies was assessed using the Newcastle-Ottawa scale.

Results: The study revealed that pGCD59 levels before 20 weeks and during the second trimester of pregnancy have the potential to predict the results of the OGTT and also forecast adverse pregnancy outcomes, such as postpartum glucose intolerance (PP GI), neonatal hypoglycaemia (NH) and having large for gestational age (LGA) infants. The predictive ability of pGCD59 was found to be affected by the GDM status, especially body mass index (BMI).

Conclusions: In conclusion, pGCD59 may be a promising indicator of glucose levels and could serve as a new biomarker for GDM. However, additional studies are needed to establish a reliable reference range and cut-off value for pGCD59.

Keywords: adverse pregnancy outcomes; biomarker; gestational diabetes mellitus; large for gestational age; pGCD59; postpartum glucose intolerance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Flow chart of literature research.
See this image and copyright information in PMC

References

    1. Gabbay‐Benziv R., “Special Issue: “Clinical Diagnosis and Management of Pregnancy Complications”,” Journal of Clinical Medicine 11, no. 19 (2022): 5644. - PMC - PubMed
    1. Modzelewski R., Stefanowicz‐Rutkowska M. M., Matuszewski W., and Bandurska‐Stankiewicz E. M., “Gestational Diabetes Mellitus—Recent Literature Review,” Journal of Clinical Medicine 11, no. 19 (2022): 5736. - PMC - PubMed
    1. Daly B. M., Wu Z., Nirantharakumar K., Chepulis L., Rowan J. A., and Scragg R. K. R., “Increased Risk of Cardiovascular and Renal Disease, and Diabetes for all Women Diagnosed With Gestational Diabetes Mellitus in New Zealand—A National Retrospective Cohort Study,” Journal of Diabetes 16, no. 4 (2024): e13535. - PMC - PubMed
    1. Yang H., Xiao C., and Tu J., “The Effect of Gestational Diabetes Mellitus on Pregnancy Outcomes in Advanced Primiparous Women: A Retrospective Study,” Medicine (Baltimore) 103, no. 13 (2024): e37570. - PMC - PubMed
    1. Xu F., Yang S., Liu Y., et al., “Placental Pathology and Neonatal Outcomes in Pre‐Eclampsia With Gestational Diabetes Mellitus,” Journal of Maternal‐Fetal and Neonatal Medicine 34, no. 7 (2021): 1149–1154. - PubMed

Publication types

LinkOut - more resources